Tubulysin and protein-tubulysin conjugates

Tubulysin-based protein conjugates effectively address resistance mechanisms in ADCs by disrupting cancer cell division, providing potent anti-cancer activity against multidrug-resistant tumors.

JP7590328B2Active Publication Date: 2024-11-26REGENERON PHARMACEUTICALS INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021535783
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-12-21
Filing Date
2019-12-20
Publication Date
2024-11-26
Estimated Expiration
2039-12-20

Smart Images

  • Figure 0007590328000877
    Figure 0007590328000877
  • Figure 0007590328000878
    Figure 0007590328000878
  • Figure 0007590328000879
    Figure 0007590328000879
Patent Text Reader

Abstract

Provided herein are compounds, compositions, and methods for the treatment of cancer-related diseases and disorders, including tubulysin and protein (eg, antibody) drug conjugates thereof.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Method for producing tubulicin derivatives and their complexes

    JP2015518473A

  • Tubricin compounds, their production and use methods

    JP2016509021A

  • Tubulysine derivatives

    US20120129779A1